Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | July 22, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 380 |
Reported balance
After 2026-07-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-22 · Grant · Acquired 380 · Balance 380 F1: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2: Annual non-employee director award. F3: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4: Not applicable as restricted stock units do not have an expiration date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22 | Direct | 1,190 |
Reported balance
After 2026-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-22 · Grant · Acquired 1,190 · Balance 1,190 F2: Annual non-employee director award. F3: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. |
| Common StockSEC Table I · non-derivative | Direct | 13,320 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,320 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
F2: Annual non-employee director award.
F3: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
F4: Not applicable as restricted stock units do not have an expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Option · Derivative | 1,190 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001108501-26-000003 · primarydocument.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,190 Underlying: Common Stock · 1,190 shares Expires 2033-07-22 F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 22, 2026 Filed Jul 23, 2026 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001108501-26-000003 · primarydocument.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 380 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001108501-26-000002 · primarydocument.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · kind: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001108501-26-000002 · primarydocument.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 4,910 | $0.00 Strike: $101.80 | $0.00 |
DisclosureSEC source: 0001108501-26-000001 · primarydocument.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,910 shares Expires 2026-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,910 | $489.02 | $2,401,088.20 |
DisclosureSEC source: 0001108501-26-000001 · primarydocument.xml · nonDerivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,670 Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:36 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 4,910 | $101.80 | $499,838.00 |
DisclosureSEC source: 0001108501-26-000001 · primarydocument.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 10:24 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 590 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005526 · primarydocument.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 10:24 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 590 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005526 · primarydocument.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 10:24 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 1,830 | $0.00 Strike: $306.41 | $0.00 |
DisclosureSEC source: 0001562180-25-005526 · primarydocument.xml · derivative · entry 4 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,830 Underlying: Common Stock · 1,830 shares Expires 2035-07-24 F4 · shares: Annual non-employee director award. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 10:24 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005526 · primarydocument.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650 Underlying: Common Stock · 650 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · shares: Annual non-employee director award. F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $175.43 | $0.00 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · derivative · entry 11 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $323.53 | $32,353.20 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 10 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,080 F9 · price: This transaction was executed in multiple trades at prices ranging from $323.46 USD to $323.58 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 750 | $322.43 | $241,820.93 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 9 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,180 F8 · price: This transaction was executed in multiple trades at prices ranging from $322.03 USD to $322.85 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,095 | $321.53 | $352,070.20 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 8 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,930 F7 · price: This transaction was executed in multiple trades at prices ranging from $321.02 USD to $322.00 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,519 | $320.43 | $486,737.58 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 7 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,025 F6 · price: This transaction was executed in multiple trades at prices ranging from $320.02 USD to $321.015 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,303 | $318.28 | $414,713.50 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 6 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,544 F5 · price: This transaction was executed in multiple trades at prices ranging from $317.84 USD to $318.705 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 897 | $317.33 | $284,646.80 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 5 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,847 F4 · price: This transaction was executed in multiple trades at prices ranging from $316.81 USD to $317.78 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,256 | $316.07 | $713,059.79 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 4 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,744 F3 · price: This transaction was executed in multiple trades at prices ranging from $315.71 USD to $316.575 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,821 | $315.26 | $1,519,849.66 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $314.71 USD to $315.70 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,259 | $314.25 | $709,899.79 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,821 F1 · price: This transaction was executed in multiple trades at prices ranging from $313.71 USD to $314.69 USD. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $175.43 | $2,631,450.00 |
DisclosureSEC source: 0001562180-25-001842 · primarydocument.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 590 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020164 · form4-07262024_040707.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590 Underlying: Common Stock · 590 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 1,440 | $0.00 Strike: $336.37 | $0.00 |
DisclosureSEC source: 0001415889-24-020164 · form4-07262024_040707.xml · derivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,440 Underlying: Common Stock · 1,440 shares Expires 2034-07-25 F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date. Read SEC document |
| July 13, 2024 Filed Jul 15, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019548 · form4-07152024_040705.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · kind: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock. F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 13, 2024 Filed Jul 15, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019548 · form4-07152024_040705.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 13, 2024. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 15,000 | $0.00 Strike: $88.03 | $0.00 |
DisclosureSEC source: 0001415889-24-005243 · form4-02262024_040211.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 15,000 | $227.03 | $3,405,450.00 |
DisclosureSEC source: 0001415889-24-005243 · form4-02262024_040211.xml · nonDerivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,180 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $88.03 | $1,320,450.00 |
DisclosureSEC source: 0001415889-24-005243 · form4-02262024_040211.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 10:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-011149 · form4-07172023_060706.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 900 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 10:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 2,280 | $0.00 Strike: $229.81 | $0.00 |
DisclosureSEC source: 0001415889-23-011149 · form4-07172023_060706.xml · derivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,280 Underlying: Common Stock · 2,280 shares Expires 2033-07-13 F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 880 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010949 · form4-07072023_040710.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · kind: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. F2 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010949 · form4-07072023_040710.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 7, 2023. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 15,000 | $0.00 Strike: $63.90 | $0.00 |
DisclosureSEC source: 0001415889-22-008464 · form4-08102022_040810.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $219.17 | $3,287,550.00 |
DisclosureSEC source: 0001415889-22-008464 · form4-08102022_040810.xml · nonDerivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $63.90 | $958,500.00 |
DisclosureSEC source: 0001415889-22-008464 · form4-08102022_040810.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2022 Filed Jul 8, 2022 21:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 3,230 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007606 · form4-07082022_020701.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2022 Filed Jul 8, 2022 21:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007606 · form4-07082022_020701.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 20:30 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 1,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007627 · form4a-07112022_040712.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,080 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock). F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F4 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 20:30 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007627 · form4a-07112022_040712.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock). F2 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 2,490 | $0.00 Strike: $240.20 | $0.00 |
DisclosureSEC source: 0001415889-22-007606 · form4-07082022_020701.xml · derivative · entry 4 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock · 2,490 shares Expires 2032-07-07 F4 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 880 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007606 · form4-07082022_020701.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880 Underlying: Common Stock · 880 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · shares: Annual non-employee director award. F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 1,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021762 · form4.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080 Underlying: Common Stock · 1,080 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders. F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F2 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:53 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 3,230 | $183.98 Strike: $183.98 | $594,255.40 |
DisclosureSEC source: 0001127602-21-021762 · form4.xml · derivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Underlying: Common Stock · 3,230 shares Expires 2031-07-08 F1 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders. F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2021 Filed Jun 28, 2021 22:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 1,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020764 · form4.xml · derivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2021 Filed Jun 28, 2021 22:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020764 · form4.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 26, 2021. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 3,750 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-21-012228 · form4.xml · derivative · entry 3 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 3,750 | $171.21 | $642,037.50 |
DisclosureSEC source: 0001127602-21-012228 · form4.xml · nonDerivative · entry 2 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,750 | $54.77 | $205,387.50 |
DisclosureSEC source: 0001127602-21-012228 · form4.xml · nonDerivative · entry 1 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 17:59 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 5,160 | $0.00 Strike: $119.76 | $0.00 |
DisclosureSEC source: 0001104659-20-078799 · a4.xml · derivative · entry 4 KURZWEIL RAY · CIK 0001108501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,160 Underlying: Common Stock · 5,160 shares Expires not disclosed F6 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F7 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F8 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.